Navigation Links
Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
Date:8/18/2009

New Molecular Toolkit Optimizes Algae Performance and Productivity

ALAMEDA, Calif., Aug. 18 /PRNewswire/ -- Today, Aurora Biofuels announces a technological milestone in the company's path to becoming the premier producer of low-cost advanced biofuels. Through a series of biotechnology achievements, Aurora has succeeded in optimizing its base algae strains to more than double CO2 consumption and fuel production, and has proven these results in an outdoor open system over the last several months.

Using tools developed in the fields of molecular biology and biochemistry, Aurora Biofuels scientists have developed a proprietary process which allows for the superior selection and breeding of non-transgenic algae. With this novel technique, the company has optimized its base algae strains with an increased ability to process sunlight and carbon dioxide into algal oil. As a result, these algae strains can produce more than twice the amount of oil. Optimized algae have been producing oil in Aurora Biofuels' outdoor pilot ponds for several months, providing strong evidence that these strains will remain robust at the industrial scale and remove more carbon emissions than previously thought possible.

"This is a major breakthrough showing that one can take algae with improved productivity from the research lab to the field. What Aurora scientists have achieved is an impressive milestone on the path to large-scale commercial algae production," said Kris Niyogi, a member of the company's scientific advisory board and professor of algal biology at the University of California, Berkeley.

"This is a game-changing development for our company, as our newly optimized algae, novel harvesting and extraction processes create a world-class, low-cost biofuel platform," said Bob Walsh, CEO of Aurora Biofuels. "There's a lot of noise about algae lately, but it's
'/>"/>

SOURCE Aurora Biofuels
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
7. NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
8. NexGen Biofuels Ltd. Announces Trading on OTC Bulletin Board
9. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
10. Performance Plants Establishes U.S. Biofuels Facility
11. NexGen Biofuels Ltd. Announces Plans to Replace its CFO With Local CFO

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...O, Nov. 20 Veridiam (www.veridiam....size company category at the 2009 Workplace Excell...iego Society for Human Resources Management and re... practices. ,, Veridiam was one of nine winners...ompanies, honored at the recent awards ceremony. S...
(Date:11/20/2009)...TLE, Nov. 20 Cell Therap...d today that the Ninth Circuit Court of Appeals re...CTI should be allowed to pursue all of its claims ...he District Court for trial. CTI filed a complain... reimbursement consultant for CTI,s product TRISEN...
(Date:11/19/2009)...N, Nov. 19 Danish Prince Joachim i...ethanol plant in Kalundborg, Denmark, on Wednesday...first and largest 2nd generation ethanol demonstra... are used in the plant,s innovative process for co...nisco, was the first to market with commercial enz...
(Date:11/19/2009)..., Nov. 19 NeoStem, Inc. ...nt the following letter to its shareholders, discu...09, of China Biopharmaceuticals Holdings, Inc. (CH...d in the People,s Republic of China. The merger gi...yre Pharmaceutical Co. Ltd., CHBP,s primary operat...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3
...mproved Technology Will Provide the Early Detectio...in Fish Farms and Wild Stocks -, HAMILTON, New Ze...une,17 ZyGEM Corp Ltd. and DIAGNOTEC S.A. today a...oduce molecular diagnostics for the,detection of i...ly pathogen,that attacks salmon and other fish spe...
...h Throughput Technology Identifies DNA Variations ... and Test Genome, OMAHA, Neb., June 17 Transgeno...t it is developing SURVEYOR,Endonuclease Adaptor-l...,throughput enabling technology for whole genome a...reference genome and a test genome. SEAL is,design...
...VER, June 17 Corgenix Medical Corporation,(OTC Bu...keter of,diagnostic test kits, announced today the...Charles H. Miranda, M.D., F.A.C.P., F.A.A.P., to i...nda join Luis Lopez, M.D., Corgenix Chairman and,C...ntific advisory board,members to three., "These t...
Other Biology Technology:ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon 2ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon 3Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 2Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 3Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 4Corgenix Expands Scientific Advisory Board 2Corgenix Expands Scientific Advisory Board 3
(Date:11/20/2009)...November 19, 2009 The estimated 4.6 million Ameri...k of developing respiratory symptoms due to poor a...naire study undertaken earlier this year by invest...eterinary Medicine. , The studywhich polled more...50 percent of individuals working in barns complai...
(Date:11/20/2009)...able in German . , In the current online is.... Stefanie Eyerich and Dr. Kilian Eyerich together...n and Istituto Dermopatico dell,Immacolata in Rome...sents a milestone on the way to developing new tre... as psoriasis and allergic reactions and potential...
(Date:11/20/2009)...new study, researchers report that a class of hear...ful, or harmful, effect on the heart, depending on...pears in the journal Circulation Research , found...d beta-receptors on the heart muscle offer the mos...rget only the beta-receptors can actually undermin...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2American Dental Association Web Survey Offers Chance at 24150 Gift Certificate 54263 1American Dental Association Web Survey Offers Chance at 24150 Gift Certificate 54263 2Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 1Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 2Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 3Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 4Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 5Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 6Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 7Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 8Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 1Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 2Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 3
...lot-dissolving medication that is administered to ...ay help to reduce the risk of amputation following...ne issue of Archives of Surgery, one of the JAMA/A...ed essentially the same for the past 25 years, acc...Today, traditional therapy consists of tissue rewa...
...at the University of Central Florida is proving pr...ucoma, an eye disease that can cause blindness and...particle can safely get past the blood-brain barri...delivery,” said Sudipta Seal, an engineering profe... Processing and Analysis Center and the Nanoscienc...
...ions and other diseases of the brain is the blood-...ed therapeutic drugs from reaching the brain. Gran...ctious Diseases, part of the National Institutes o...tide) from the rabies virus can carry a strip of t... administration. Once delivered to the nerve cells...
Other Biology News:Clot-dissolving agent may be beneficial in treatment of severe frostbite 2UCF nanoparticle offers promise for treating glaucoma 2Blood-brain barrier breached by new therapeutic strategy 2
Rat Anti-Mouse Axl Monoclonal Antibody, Unconjugated, Clone 175128 from R&D Systems
Rabbit Anti-Human RXRA Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Human M-CSF from BioVision
Mouse Anti-Human IL-19 Monoclonal Antibody, Unconjugated, Clone 152112 from R&D Systems
Biology Products: